Introduction
Despite the recent characterization of the human genome and subsequent identification of genetic abnormalities in certain human diseases, the ability of current gene therapy protocols to correct these is currently being limited by their poor specificity for, and penetration into, the diseased tissue. Many forms of gene delivery vehicles have been developed including synthetic and viral vectors, and cell-based approaches, but these often fail to penetrate much beyond the vasculature of the target tissue when administered systemically and thus have limited efficacy in vivo. 1 The use of human cells as cellular delivery vehicles for anti-cancer gene therapy has long been considered to be an attractive approach to the treatment of tumours due to the reduced immunogenicity and toxicity of using the patient's own cells. 2 We and others have suggested that macrophages (or their precursor cells in the bloodstream or monocytes) could be used in this way as various studies have shown that monocytes enter malignant tumours in large numbers, differentiate into macrophages and accumulate in avascular hypoxic/necrotic areas. 3, 4 This means that they could be used to deliver gene therapy to these otherwise inaccessible (that is, poorly vascularized) areas in tumours. We have demonstrated the potential of this approach in vitro by infiltrating the inner, hypoxic areas of breast tumour spheroids with monocyte-derived macrophages armed with a hypoxia-driven DNA construct encoding the prodrug-activating enzyme, cytochrome P4502B6. When these cells experienced hypoxia inside spheroids they expressed the enzyme, so when spheroids were exposed to the prodrug cyclophosphamide, it was converted to a cytotoxic drug and triggered significant tumour cell destruction within the tumour mass. 5 However, to date, there has been little evidence to show that monocytes or macrophages manipulated ex vivo are capable of trafficking to the tumour site in sufficient numbers to elicit a therapeutic effect. 6, 7 For example, macrophages stimulated with cytokines to be cytotoxic towards tumour cells in vitro largely became trapped in the fenestrated capillaries of the liver, lungs and kidneys following re-infusion into tumour-bearing mice 6, 8 or cancer patients. 7, 9 This prompted us to develop a way to use ultra-small, biocompatible magnetic particles (otherwise known as magnetic nanoparticles (MNPs)) to enhance the overall uptake of genetically engineered cells like monocytes or macrophages by tumours following their systemic administration.
As early as 1960, Freeman 10 proposed that such MNPs could be transported through the vascular system and concentrated in a specific part of the body using an externally-applied magnetic field. Since then, MNPs have been conjugated to various therapeutic agents like the anti-cancer drug, doxorubicin and a magnetic field applied to the target tissue in an attempt to enhance drug delivery to that site. 11, 12 The problem with this approach has been that, although the drug is concentrated within the target tissue by the magnet, relatively little penetrates beyond the peri-vascular regions, so the deeper regions of the tissue remained untreated. 13, 14 The degree of infiltration of a diseased tissue by inflammatory cells in vivo has also been achieved using magnetic resonance imaging of MNP-loaded cells. 15, 16 Here, we have used two new in vitro models of monocyte extravasation and an in vivo human tumour model to show, for the first time, that MNPs can also be used to enhance the uptake of genetically modified monocytes by tumours.
In this novel approach, monocytes are loaded with MNPs and a magnetic field is generated above or near the tumour to attract these 'magnetic' monocytes to the area ( Figure 1 ). We propose that this new magnetic targeting approach could be used to target 'therapeutically armed' monocytes (and potentially other forms of cellular gene delivery vehicles) to tumours, and thus overcome the hurdle of poor targeting in current cellbased gene therapy protocols.
Results

Uptake of magnetic nanoparticles by human monocytes in vitro
Monocytes are 'professional' phagocytes that are capable of ingesting large quantities of particulate matter by phagocytosis including super-paramagnetic particles. 17 We co-cultured human monocytes in the presence of (25 nM) gFe 2 O 3 MNPs and found these to be readily internalized in a dose-dependent manner within 1 h of incubation as determined by acridine orange and Prussian blue staining (data not shown). Indeed, when MNPs were conjugated to Nile red and taken up by human monocytes, fluorescent microscopy ( Figure 2a ) and flow cytometry (Figure 2b) showed that 70-90% of monocytes contained MNPs. We then tested whether these MNP-loaded monocytes would be attracted to a magnetic field in vitro by dropping them slowly into a culture vessel that had a magnet placed to one side. Within 10 min, significant attraction of the cells towards the magnet could be seen (Figure 2c and inset) and was persistent for up to 72 h (data not shown). We then investigated whether the uptake of MNPs would have a cytotoxic effect of on monocytes by exposing them to different concentrations (1-1000 mg ml
À1
) of MNP for 24 h and then washing and staining them with a propidium iodide a marker for cell death (cell uptake being visualized by flow cytometry). At concentrations below 250 mg ml
, cell viability was similar to that in untreated monocytes (Figure 2d ). Other studies have also demonstrated that uptake of MNPs by monocytes is not cytototoxic. 16 The intracellular iron content in monocytes increased with increasing concentrations of MNPs applied to cells (data not shown) as determined by Inductively Coupled Plasma Atomic Emission Spectroscopy using Varian Vista-M PX. The iron content of cells exposed to 100 mg ml À1 MNPs (1.18 mg ml À1 ±0.3) was not cytotoxic to cells (Figure 2d ) and did not alter monocyte morphology in culture or expression of monocyte marker CD14 (as expressed by flow cytometry, data not shown). We, therefore, used 100 mg ml À1 of MNPs in all subsequent experiments in this study.
Taken together, these data indicate that the uptake of MNPs by monocytes is rapid, effective and had no detectable deleterious effects on monocyte function.
Enhanced migration of MNP-loaded monocytes into tumours in the presence of a magnetic field
We then tested the ability of MNP-loaded monocytes to migrate across a layer of human endothelial cells (EC) Magnetic cell-based gene therapy M Muthana et al in vitro, and whether this could be enhanced by the application of a magnetic field. To do this, we designed a new in vitro monocyte extravasation assay (illustrated in Figure 3 ) in which monocytes migrate across such an EC layer and then infiltrate into tumour spheroids (generated previously in non-adherent cultures of the breast human tumour cell line, T47D). At the end of the assay, flow cytometry of cells produced by enzymatic dispersion of spheroids indicated that MNP-loading of monocytes had no significant effect on the ability of human monocytes to migrate across an EC layer or infiltrate into spheroids in this assay (data not shown).
More importantly, however, we needed to ascertain whether monocytes transfected with an exogenous gene and then loaded with MNPs would also display similar functions in the assay, and whether this would be increased if a magnetic field was applied close to the bottom chamber (that is, near the spheroids). This would then provide proof of principle data that recruitment of transfected monocytes into a three-dimensional (3D) tumour mass could be enhanced using our magnetic approach.
First, monocytes were transfected with a CMV-driven reporter (green fluorescent protein or GFP) using the The format of a new, in vitro extravasation assay in which human monocytes migrate across an endothelial cell layer into tumour spheroids. Transwell inserts with a 3 mM-pore PET membrane were coated with human dermal microvascular endothelial cells (HuDMECs) and positioned in 24-well plates. Tumour spheroids of 700-800 um in diameter were generated in non-adherent cultures of the human breast tumours cell line, T47D, and added to the lower chamber of the transwell. One million monocytes pre-loaded with magnetic nanoparticles (MNPs) were then placed in the upper chamber, in the presence/absence of a magnetic field applied underneath (to attract MNP-loaded monocytes across the HuDMEC layer into spheroids). MNPs. Monocytes were seen to maintain their ability to express this level of GFP for up to 48 h post-transfection ( Figure 4b ). GFP-transfected, MNP-loaded monocytes were then added to the upper chamber of the assay shown in Figure 3 , allowed to migrate across this EC barrier into spheroids for 24 h (in the presence or absence of magnetic field placed directly below the culture vessel as presented schematically in Figure 3 ), spheroids were collected and analysed for monocyte infiltration by flow cytometry and/or immunohistochemistry. Figure 4 shows that CD68+ (panel c) and GFP-expressing (panel d) monocytes were abundant in spheroids when a magnetic field was applied in the assay. The monocytes were seen in the outer well-oxygenated areas as well as the central necrotic and hypoxic sites of spheroids. Very few EC were detected in the spheroids as determined by staining of spheroid sections using the endothelial cell marker CD31 (data not shown). Flow cytometric analysis of cells from enzymatically dispersed spheroids in parallel assays to those described above showed that in the absence of a magnet approximately 15% GFP-expressing MNP-loaded monocytes infiltrated the spheroid (Figure 4e ), this is more or less the same as GFP-expressing monocytes alone (data not shown). However, the application of a magnetic field elicited a significant (Po0.006) increase in the number of GFP-expressing monocytes infiltrating spheroids ( Figure  4e ). This shows that the 'magnetic' approach used in these studies was able to induce more monocytes to move across the EC (human dermal microvascular endothelial cells or HuDMEC) layer and infiltrate a 3D tumour mass like spheroid in vitro.
Adhesion of MNP-loaded monocytes to endothelial cells under conditions of venous flow
We then conducted adhesion assays using a novel, parallel flow chamber. This allowed us to perfuse MNP-loaded monocytes over an EC layer in the presence or absence of a magnetic field, thus, mimicking their passage through flowing blood vessels. In this assay we could visualize the effect of a magnetic field on the adherence of MNP-loaded, GFP-expressing monocytes as they passed across a layer of human EC at a typical venous flow rate (1.1885 ml min
À1
). The introduction of a magnet below the EC in this assay resulted in a massive and significant (Po0.001) increase in the adherence of circulating GFP+ monocytes to the EC layer as compared to when no magnet was present (Figures 5a and b) . Furthermore, many of these cells remained firmly attached even after the magnetic field had been removed Magnetic cell-based gene therapy M Muthana et al ( Figure 5 ). As expected, non MNP-loaded monocytes failed to respond to the magnetic field (data not shown).
Uptake of MNP-loaded, transfected monocytes by tumours in vivo
For this magnetic approach to have relevance to the tumour targeting of transfected monocytes in vivo, we also needed to show that it could increase the uptake of such cells into tumours in vivo. Flow cytometry of enzymatically dispersed PC3 tumours grown in nude mice following intravenous injection of mice with MNPloaded, GFP-expressing human monocytes showed that significantly more of these cells were present when an external magnet was applied to tumours (Figures 6a and  b) . The number of untreated monocytes infiltrating the tumour (typically 2-4%) was very similar to the number of infiltrating GFP-expressing monocytes in the absence of a magnetic field (data not shown). In addition, the proportion of the total cell mass expressing CD14+ GFP+ cells increased from 4.9%±3.5 (no external magnet) to 16.9% ± 4.2 (magnet present). Only a negligible number (less than 1%) of cells from enzymatically dispersed normal tissues from the same tumour-bearing mice (liver, kidney and spleen) were seen to be GFP+ (data not shown). Thus, the majority of injected GFP-expressing monocytes had targeted specifically to the tumour when an external magnet was applied close to it ( Figures  6 c-e) . Although a small number of GFP-expressing monocytes were detected in tumours by immunofluorescent staining in the absence of a magnet (Figure 6d ), this markedly increased in the presence of an external magnet (Figure 6e) . Interestingly, large numbers of GFPexpressing monocytes were detected in hypoxic, perinecrotic areas as revealed by CD68 and anti-GFP staining (Figures 6c and e) suggesting that the delivery of therapeutic genes to such poorly vascularized (and thus usually inaccessible) sites could be enhanced using this approach. In addition, the magnetically enhanced uptake of these cells into tumours was not associated with any signs of microscopic damage to vessels of other areas of tumours.
Discussion
In this report, we describe a new 'magnetic' approach to enhancing the uptake of genetically modified cells by a target tissue. It is envisaged that this new method could be used to overcome the problem of poor uptake of cellbased forms of gene therapy by diseased tissues like malignant tumours.
Initially, we devised a novel in vitro assay in which transfected primary human monocytes migrate across a human endothelial cell layer into a 3D human tumour mass (spheroid). We then showed that when monocytes were loaded with MNPs, this had little or no effect on their function or viability, but markedly increased their adhesion to EC, migration across an EC layer and infiltration into tumour spheroids in response to an externally applied magnetic field. Indeed, MNP-loaded, transfected monocytes were attracted deep into the hypoxic inner layers of spheroids in these studies. These avascular, hypoxic areas in tumours are notoriously difficult to treat using conventional therapies so our magnetic approach could be used to enhance the cellbased delivery of genes to these otherwise inaccessible tumour sites.
Although the topical application of a magnetic field to a tumour has been shown to augment the delivery of MNP-conjugated pharmaceutical drugs to such sites, 11, 18 our report is the first to use MNPs to enhance the delivery of transfected cells to tumours. If the target site cannot be reached with a magnet, then a local magnetic field could still be achieved using implanted ferromagnetic stents. 19 Our data also show that this magnetic approach could be used to make cells slow down and adhere to an EC layer under flow conditions that mimic their rate of passage in post capillary venules. Various studies have shown that both the adhesion of monocytes, and their subsequent extravasation into surrounding tissues, occurs mainly at these sites due to the low wall shear stress in such vessels. 20 MNP-loaded monocytes showed 250-fold greater adhesion to EC in the presence of a magnetic field, with a significant proportion (440%) of these remaining firmly attached under flow conditions after the magnet had been removed. Various studies have shown that such increased adhesion of monocytes to EC in blood vessels leads to an increase in their extravasation into surrounding tissues. 21, 22 One important consideration for the in vivo efficacy of this approach would be the retention of the MNPs by the cellular vehicle. In our studies, MNP-loaded primary human monocytes continued to show enhanced migration in response to a magnetic force for up to 72 h suggesting that the cells retained sufficient MNPs to remain 'magnetic' for this period of time. As most human monocytes extravasate into tissues within 24 h of circulation in the bloodstream, 23 the retention of MNPs for 72 h by monocytes should be sufficient to allow their uptake by the target tissue. Interestingly, others have shown persistent retention of MNPs by other human cell types for several days. 24 Indeed, our magnetic method was able to increase the delivery of transfected monocytes to tumours within 5 h of their injection into tumour-bearing mice, and without causing any signs of microscopic tissue damage. This is a marked improvement on the use of 'naked' MNPs conjugated to DNA or drugs as these often cause extensive tissue damage 12 and show poor penetration far beyond the tumour vasculature. 11 Interestingly, our magnetic, GFP-expressing monocytes were able to reach poorly vascularized (that is, hypoxic) peri-necrotic areas of tumours which are notoriously difficult to target with viral or non-viral gene therapy vectors, indicating the potential therapeutic benefits of this technology. Previous studies have shown that various forms of cellular vector being developed for use in cell-based gene therapy protocols can be loaded with MNPs ex vivo including dendritic cells, 25 hematopoietic stem cell progenitors, 24 EC 26 and T cells. 27 To date, these MNP loaded cells have largely been used for imaging cells/tissues in vivo, but our data suggests that it might also be possible to use our magnetic targeting Magnetic cell-based gene therapy M Muthana et al approach to increase their targeting to diseased sites in cell-based gene delivery. In sum, the results from our study are the first to outline a magnetic guidance strategy for increasing the trafficking of cells carrying therapeutic genes to target tissues. Such an approach could markedly improve the efficacy of cell-based gene delivery protocols.
Materials and methods
Isolation and culture of human monocytes
Mononuclear cells were isolated from platelet-depleted buffy coats (Blood Transfusion Service, Sheffield, UK) using the RosetteSep assay (StemCell Technologies, Vancouver, Canada) and Ficoll-Paque Plus (Amersham Pharmacia, St Albans, UK) as described by us previously. 28 The purity of monocytes in these cell preparations was found to be routinely 497% as assessed by flow cytometry using antibodies to the pan-monocyte marker, CD14 (AbD Serotec, Oxford, UK).
Endothelial cell cultures
Human Dermal Microvascular Endothelial Cells were obtained from Promocell, (Heidelberg, Germany) and cultured in Promocell's microvascular endothelial cell growth medium with supplement (consisting of basic fibroblast growth factor, endothelial cell growth supplement/heparin, epidermal growth factor, hydrocortisone and foetal calf serum). HuDMEC were used in the experiments up to passage 8. At confluence, cells were harvested with trypsin-EDTA (Promocell) and 150 000 cells were seeded for 24 h onto collagen-coated (0.1 mg ml
À1
, human type IV) transparent migration chamber inserts containing a 3 mM pore PET membrane (BD Falcon, Oxford, UK) and then washed to remove non-adherent HuDMEC. This resulted in a confluent monolayer of HuDMEC on filters as seen by CD31 staining of filters (data not shown).
Human tumour spheroids
The microenvironments present in small, avascular tumours can be mimicked in vitro by the generation of small, 3D tumour masses called tumour spheroids grown from non-adherent cultures of human tumour cells. These contain an outer well-oxygenated area and an inner, hypoxic/necrotic one. In this study, tumour spheroids were generated by growing the human breast tumour cell line, T47D, initially as a monolayer culture in Dulbecco's modified Eagle's medium (Gibco, Paisley, UK) supplemented with 10% foetal calf serum and 2 mm glutamine. Spheroids were then prepared by seeding 5 Â 10 3 of these cells in 100 ml medium into each well of a 2% molecular biology grade agarose (Sigma, Dorset, UK) coated 96-well tissue culture plate. After 7-10 days, each well contained a tumour spheroid with an average diameter of 700-800 mm.
Transfection of primary monocytes
For AMAXA transfection experiments, freshly isolated monocytes were resuspended at 10 6 -10 7 cells/transfection in AMAXA buffer and electroporated with 1 mg DNA (pmaxGFP) as per manufacturer's protocol (AMAXA Biosystems, Cologne, Germany) using the AMAXA nucelofection machine. Cells were analysed 24 h later by fluorescent microscopy and flow cytometry for GFP expression; this was routinely between 45-55%. Transfected monocytes were shown to be 85% viable at this stage by co-staining with propidium iodide (Sigma, Surrey, UK) and flow cytometry.
Cellular uptake of magnetic nanoparticles by monocytes
For the nanoparticle cellular uptake studies, one million purified monocytes (or GFP transfected monocytes) were cultured overnight in 24-well plates in Iscove's modified Dulbecco's media (Gibco BRL, Paisley, UK) containing 2% human AB serum (Sigma, Poole, UK) and MNPs 100 mg ml À1 MNPs (25 nm) (Sigma-Aldrich, Poole, UK). Cells were washed several times in phosphate buffered saline (PBS) to remove free MNP, fixed with 3% cold gluteraldehyde and stained with acridine orange to determine the relative amount of internalized MNP, and counterstained with Prussian blue. Monocyte cytoplasm stained pale orange, whereas the nuclei stained dark orange. To determine the relative amount of iron internalized, fixed cells were counterstained with Prussian blue. Intracytoplasmic MNPs had a blue green colour, whereas free MNPs stained blue.
Nanomagnetic particle accumulation in monocytes following incubation with 100 mg ml À1 MNPs labelled with Nile red dye (360 nm; Spherotech Inc. Lake Forest, USA) was also assessed by fluorescent microscopy and flow cytometry. The magnetic properties of MNP-loaded monocytes was confirmed by attraction of the cells towards a magnet placed at the side of the culture dish as observed by light microscopy (Leica Microsystems, Milton Keynes, UK). The viability of MNP-loaded monocytes was determined 24 h after exposure to 100 mg ml À1 MNPs by flow cytometrical analysis with PI. To determine the iron content within MNP-loaded monocytes, cell pellets were solubilized in 70% nitric acid for 7-14 days prior to analysis. Iron concentrations were quantified against a calibration standard iron solution (Fischer Scientific, Loughborough, UK) by Atomic Emission Spectroscopy using Varian Vista-M PX.
In vitro monocyte extravasation assay
Six T47D spheroids were added to each well of a 24-well plate previously coated with agarose (to make it nonadherent to cells and thus hold spheroids in suspension). Transwell inserts coated 24 h earlier with the HuDMECs were positioned above spheroids and 1 Â 10 6 monocytes added to the upper chamber and incubated for 24 h at 37 1C in the presence or absence of a magnet (Magnet Sales and Services Ltd, Swindon, UK) below the bottom chamber. This simulated the passage of monocytes across EC in a blood vessel wall. The filter was then removed and spheroids removed from the lower chambers, these were washed in PBS to remove excess monocytes from the spheroid surface. Spheroid infiltration by monocytes was then assessed using two methods: (i) Immunohistochemical analysis-spheroids were fixed in 10% buffered-formalin, wax embedded, sectioned and immunostained for pan-macrophage marker, CD68 (AbD Serotec) using the catalysed signal amplification system (Dako, Ely Cambridgeshire, UK). (ii) Flow cytometry-spheroids were enzymatically dispersed using 0.25% trypsin/EDTA, the resultant cell suspension washed repeatedly, and the proportion of CD14+ monocytes present in the total cell population assessed by flow cytometry. All cell culture experiments were carried out in triplicate wells and five or more independent experiments were performed.
In vitro flow assay
To provide a suitable substrate for endothelial cell culture, glass microslides (Camlab, Cambridge, UK) were autoclaved and coated with 2 Â 10 À4 mg ml ) were seeded directly onto these and grown for 48 h or until confluent. They were then incubated with recombinant human TNF-a at 50 U ml À1 (NIBSS, Hertfordshire, UK) for 4 h (to activate integrin expression by EC and thus enhance monocyte adhesion). 29 Slides were attached to the bottom of a rectangular flow chamber system (Glycotech, MD, USA) by vacuum before mounting on the stage of an inverted microscope (Zeiss Axiovert, Vero Beach, FL, USA; 200 M) enclosed in a heated (37 1C) environmental chamber. Monolayers were washed by perfusion for 5 min with pre-warmed PBS + 2% foetal calf serum using a syringe pump system (Harvard Apparatus, MA, USA). Monocytes or MNPloaded monocytes (1.5 Â 10 5 cells ml À1 in PBS+2% foetal calf serum) were then flowed over the HuDMEC monolayer at typical venous flow rates (1.1885 ml min , this is equivalent to blood flow through post-capillary venules. 30 The magnet was positioned directly below the microscope slide (distance from magnet was 120 mm, magnet strength was 3 mT). Video images of a single field of view ( Â 20) were captured in real-time (15 frames per second) for 10 min of monocyte perfusion, so that the adhesion of individual monocytes to the endothelial monolayer could be quantified in the absence or presence of a magnetic field, and following removal of the magnetic field (for 15 min). The total number of firmly adhered monocytes per field of view (in 10 separate fields) was calculated using AxioVision cell tracking analysis software (Carl Zeiss Inc., Hertfordshire, UK).
Macrophage trafficking to tumour xenografts in vivo
Human prostate tumour (PC3) cells were harvested when 80% confluent. Male MF1 athymic mice (aged 6-8 weeks) were obtained from Harlan laboratories, (Bicester, UK) and injected sub-cutaneously in the left flank with 2 Â 10 6 cells in a volume of 100 ml. When tumours reached a mean group size of 70-100 mm 3 they were injected with MNP-loaded, CMV-GFP-transfected human monocytes (prepared as described above). Three million cells were administered via the tail vein in 100 ml volume of PBS, control groups received 100 ml PBS, or 100 ml PBS containing 3 Â 10 6 untreated monocytes. For some mice, magnets were positioned centrally over the surface of the tumour immediately following monocyte administration and remained in this position until mice were killed 5 h later. Tumours and various normal tissues (liver, kidney, spleen and so on) were then removed and divided into two; one half being snap frozen for immunostaining/fluorescent analysis and the other dissected free of adherent fibrous and fatty tissue and subjected to fine mincing. The latter were passed through a sterile sieve, and the cell suspension was collected in PBS. The cell suspension, after counting, was incubated with anti-CD14 at 4 1C for 30 min, then analysed by flow cytometry for the expression of GFP. For the microscopic studies, 7 mm frozen sections of tumours were cut and stained with human anti-CD68 as described above or rabbit anti-GFP (Invitrogen, Paisley, UK) followed by secondary donkey anti-rabbit alexafluor488 (Invitrogen) and mounted with Vectashield containing DAPI (Vector Laboratories, Peterborough, UK).
Statistical analysis
Data are means±s.e.m. Student's t-test was used to analyse the statistical significance of the data. Differences were termed a significant P-value of less than 0.05.
